Hyperfine (HYPR) announced the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center clinical study designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI. The study is intended to support a future FDA submission to expand the Swoop system’s intended use to include gadolinium-based contrast agents. The primary objective of the study is to evaluate the visualization of brain lesions, including lesions associated with blood-brain barrier disruption, using contrast agents with ultra-low-field portable MRI. Visualization benefits will be assessed using three endpoints related to lesion appearance. The study will enroll approximately 70 patients across multiple sites in the United States.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR:
- Hyperfine Announces Strong Preliminary Q4 2025 Revenue Growth
- Hyperfine reports preliminary Q4 revenue $5.3M, consensus $5M
- Hyperfine Expands ATM Equity Offering With New Sales Agent
- Hyperfine announces regulatory approval of Swoop System in India
- Hyperfine gets FDA clearance for diffusion-weighted imaging software sequence